ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $53.67 and traded as high as $55.56. ProShares Ultra Nasdaq Biotechnology shares last traded at $54.60, with a volume of 7,479 shares.
ProShares Ultra Nasdaq Biotechnology Trading Down 2.0 %
The stock has a 50 day moving average of $53.80 and a 200-day moving average of $58.55.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
The business also recently announced a dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 23rd were paid a dividend of $0.3964 per share. This is a positive change from ProShares Ultra Nasdaq Biotechnology's previous dividend of $0.15. The ex-dividend date was Monday, December 23rd.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its position in shares of ProShares Ultra Nasdaq Biotechnology by 31.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,326 shares of the exchange traded fund's stock worth $270,000 after acquiring an additional 1,266 shares during the period. Crowley Wealth Management Inc. purchased a new position in ProShares Ultra Nasdaq Biotechnology during the 4th quarter worth $51,000. Finally, Jane Street Group LLC raised its position in ProShares Ultra Nasdaq Biotechnology by 8.4% during the 3rd quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund's stock valued at $306,000 after purchasing an additional 374 shares in the last quarter.
ProShares Ultra Nasdaq Biotechnology Company Profile
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
See Also
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
